Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial have?
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial has 172 citations in the OpenAlex counts ScholarIQ stores.
When was Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial published?
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial has 2020 year in the ScholarIQ index.
What is the open-access status of Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial?
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial has green oa status in the ScholarIQ index.
What is the DOI of Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial?
The DOI for Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial is on the source record.
What is the OpenAlex record for Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial?
The OpenAlex for Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial is on the source record.